FRIDAY, SEPTEMBER 19TH

PREVENTIVE AND DISEASE MODIFYING TRIALS

CHAIRMEN : Y. STERN (NEW YORK), Z. KHACHATURIAN (LAS VEGAS)

ORAL COMMUNICATIONS

08:00
010 MAPT: MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL. STUDY DESIGN
S. GILLETTE (1,3), G. ABELLAN VAN KAN (1), I. CARRIE (1), M.E. SOTO (1), J. GARDETTE (2), C. PRZYBYLSKI (2), S. ANDRIEU (1,3,4), and B. VELLAS (1,3) for the MAPT study investigators
(1) Gérontopôle, Department of Geriatric Medicine, CHU Toulouse, F-31059, France; (2) Institute de Recherche Pierre Fabre; (3) Inserm U-558, University Toulouse III, F-31073, France; (4)
Department of Epidemiology and Public Health, University III, F-31073, France

08:15
011 FISH CONCUMPTION AND COGNITIVE FUNCTION AMONG OLDER PEOPLE IN THE UK: ANALYSIS OF BASELINE DATA FROM THE OPAL STUDY
Alan D Dangour (1*), Elizabeth Allen (1), Diana Elbourne (1), Astrid Fletcher (1), Marcus Richards (2) and Ricardo Uauy (1)
(1) Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine; (2) Department of Epidemiology and Public Health, University College London
* Presenting author: Nutrition and Public Health Intervention Research Unit, Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK

LECTURES

08:30
L13 Can we increase cognitive reserve to treat or prevent Alzheimer’s disease ?
Yaakov STERN (New York)

09:00
L14 MCI: a good target for preventive trials ?
Jacques TOUCHON (Montpellier)

09:30
L15 An update on Disease Modifying Trials
Bruno VELLAS (Toulouse)

10:00 - 10:30
Coffee break and Poster Session

NEW THERAPIES

CHAIRMEN : L. SCHNEIDER (LOS ANGELES), P. AISEN (SAN DIEGO)

10:30
L16 Results of the LEADe study
Howard FELDMAN (Vancouver)

11:00
L17 New therapy with stem cells
Bengt WINBLAD (Stockholm), Roxana NAT (Stockholm)

11:30
L18 Gama secretase inhibitor clinical research
Eric SIEMERS (Philadephia)

12:00
L20 New and future therapies for Alzheimer’s disease
Ezio GIACOBINI (Geneva)

12:30
L19 Results of the US Phase II Trial of Huperzine A in Mild to Moderate Alzheimer's disease
Paul AISEN (San Diego)

13:00 - 14:00
Lunch time

ORAL COMMUNICATIONS

14:00
014 A COMBINATION OF GALANTAMINE PLUS MEMANTINE IN AMCI EXERTS POSITIVE COGNITIVE EFFECTS MOST PRONOUNCED IN PRESUMED PREDEMENTIA AD
O. PETERS (1), D. LORENZ (1), H.J. MÖLLER (2), L. FRÖLICH (3), I. HEUSER (1)
(1) Department of Psychiatry and Psychotherapy, Charité-CBF, Berlin, Germany; (2) Department of Psychiatry and Psychotherapy, LMU Munich, Munich, Germany; (3) CIMH Mannheim, University of Heidelberg, Mannheim, Germany.

14:15
015 PHASE I STUDY OF THE 18F-LABELLED BENZOTHIAZOLE DERIVATIVE [18F]AH110690 AS AN IN VIVO BIOMARKER OF AD-RELATED BRAIN AMYLOIDOSIS
R VANDENBERGHE (1), L THURFJELL (2), R OWENIUS (2), DJ BROOKS (2), N NELISSEN (1), M KOOLE (3), G BORMANS (3), K VAN LAERE (3)
(1) Neurology and (3) Nuclear Medicine Department, University Hospitals Leuven & K.U.Leuven, Leuven, Belgium; (2) GE Healthcare, Medical Diagnostics, Research and Development, Amersham, United Kingdom / Uppsala, Sweden.

14:30
016 PROOF OF CONCEPT STUDY OF PLASMA EXCHANGE WITH 5% HUMAN ALBUMIN GRIFOLS® IN THE TREATMENT OF PATIENTS WITH MILD ALZHEIMER’S DISEASE
M. BOADA (1,2), J. MUÑOZ (3), L. TÁRRAGA (1), P. ORTIZ (3), I. HERNÁNDEZ (1), J. BECKER (4), O. LÓPEZ (4), M. BUENDIA (1), R. PLA (3), J.R. GRIFOLS (3), A. PAEZ (5), L. NÚÑEZ (5), I. FERRER (6)
(1) ACE Foundation, Catalan Institute of Applied Neurosciences, Barcelona; (2) Neurology Service, University General Hospital Vall d’Hebron, Barcelona; (3) Blood and Tissue Bank, University General Hospital Vall d’Hebron, Barcelona; (4) Alzheimer’s Disease Research Centre, University of Pittsburgh, (5) Grifols Institute, Barcelona; (6) Neuropathology Institute, University General Hospital Bellvitge, Barcelona, Spain.

14:45
Coffee break and Poster session

NETWORK IN ALZHEIMER’S DISEASE

Symposium of the German Competence network on dementias (CND)
Chairs: Eckart Ruether, Lutz Froelich

15:15
S1 Structure and scope of the CND
Wolfgang MAIER (Bonn)

15:35
S2 Studies on early and differential diagnosis of Alzheimer‘s disease
Johannes Kornhuber (Nuremberg), Jens Wiltfang (Duisburg)

16:00
S3 Multi-center MR spectroscopy for predictive dementia diagnosis
Frank Jessen (Bonn)

16:20
S4 Clinical trials on combination therapy in Alzheimer’s disease and MCI
Isabella Heuser (Berlin), Lutz Froelich (Mannheim)

16:45
Summary and clinical conclusions
Eckart Ruether (Munich)